Dataset Information


The role of anti-vascular endothelial growth factor (anti-VEGF) in the management of proliferative diabetic retinopathy.

ABSTRACT: Diabetes is a major cause of visual impairment among working-age adults in the United States. The proliferative form of diabetic retinopathy is associated with severe vision loss (acuity <5/200). The standard treatment in proliferative diabetic retinopathy (PDR) is panretinal photocoagulation (PRP), which is effective but has established side effects such as peripheral visual-field constraints. Vascular endothelial growth factor (VEGF) is thought to drive the process of vascular proliferation. Drugs targeting VEGF (anti-VEGF) have been studied extensively in diabetic macular edema (DME), and results have shown that diabetic retinopathy regresses with anti-VEGF treatment. Recent studies show that anti-VEGF is not inferior to PRP for PDR while treatment is maintained, though recurrence rate when anti-VEGF treatment is stopped is unclear. In vitreous hemorrhage where PRP cannot be performed, use of anti-VEGF medications can treat underlying PDR and delay or reduce need for vitrectomy. Limitations of anti-VEGF treatment, however, require careful patient selection and monitoring. This review discusses recent clinical trials and guidelines for anti-VEGF use in PDR.


PROVIDER: S-EPMC6113746 | BioStudies | 2018-01-01


REPOSITORIES: biostudies

Similar Datasets

2019-01-01 | S-EPMC6947741 | BioStudies
2017-01-01 | S-EPMC6648671 | BioStudies
2020-01-01 | S-EPMC7289996 | BioStudies
2020-01-01 | S-EPMC7031713 | BioStudies
1000-01-01 | S-EPMC4017101 | BioStudies
2019-01-01 | S-EPMC6936773 | BioStudies
2020-01-01 | S-EPMC7566633 | BioStudies
1000-01-01 | S-EPMC4999649 | BioStudies
2017-01-01 | S-EPMC5540054 | BioStudies
2018-01-01 | S-EPMC6233839 | BioStudies